APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Next-Generation Tumor Genetic Testing

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Next-Generation Tumor Genetic Testing Market Analysis and Forecast 2026-2032

Report ID 17419734022 May 2026217 pages

Choose your research edition.

Industry ResearchNext-Generation Tumor Genetic Testing Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Next-Generation Tumor Genetic Testing Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Next-Generation Tumor Genetic Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Next-Generation Tumor Genetic Testing Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Next-Generation Tumor Genetic Testing Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global Next-Generation Tumor Genetic Testing market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Next-Generation Tumor Genetic Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Next-Generation Tumor Genetic Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Next-Generation Tumor Genetic Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Next-Generation Tumor Genetic Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Next-Generation Tumor Genetic Testing include Devyser, Agendia, Illumina, Personal Genome Diagnostics, Veracyte, Pacific Biosciences of California, Qiagen, Agilent Technologies and Natera, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Next-Generation Tumor Genetic Testing, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Next-Generation Tumor Genetic Testing, also provides the revenue of main regions and countries. Of the upcoming market potential for Next-Generation Tumor Genetic Testing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Next-Generation Tumor Genetic Testing revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Next-Generation Tumor Genetic Testing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Next-Generation Tumor Genetic Testing revenue, projected growth trends, production technology, application and end-user industry.

Next-Generation Tumor Genetic Testing Segment by Company

Devyser

Agendia

Illumina

Personal Genome Diagnostics

Veracyte

Pacific Biosciences of California

Qiagen

Agilent Technologies

Natera

Bio Rad Laboratories

Myriad Genetics

Next-Generation Tumor Genetic Testing Segment by Type

Fluorescence In Situ Hybridization

Polymerase Chain Reaction

Microarray Technology

Serum Proteomics

Nucleic Acid Sequencing

Next-Generation Tumor Genetic Testing Segment by Application

Hospitals

Speciality Clinics

Research Institutes

Diagnostics Laboratories

Biopharmaceutical Companies

Next-Generation Tumor Genetic Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Next-Generation Tumor Genetic Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Next-Generation Tumor Genetic Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Next-Generation Tumor Genetic Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Next-Generation Tumor Genetic Testing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Next-Generation Tumor Genetic Testing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Next-Generation Tumor Genetic Testing revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Next-Generation Tumor Genetic Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Fluorescence In Situ Hybridization Major Player Table 3. Polymerase Chain Reaction Major Player Table 4. Microarray Technology Major Player Table 5. Serum Proteomics Major Player Table 6. Nucleic Acid Sequencing Major Player Table 7. Global Next-Generation Tumor Genetic Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospitals Major Player Table 9. Speciality Clinics Major Player Table 10. Research Institutes Major Player Table 11. Diagnostics Laboratories Major Player Table 12. Biopharmaceutical Companies Major Player Table 13. Next-Generation Tumor Genetic Testing Industry Trends Table 14. Next-Generation Tumor Genetic Testing Industry Drivers Table 15. Next-Generation Tumor Genetic Testing Industry Opportunities and Challenges Table 16. Next-Generation Tumor Genetic Testing Industry Restraints Table 17. Global Next-Generation Tumor Genetic Testing Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 18. Global Next-Generation Tumor Genetic Testing Market Size by Region (2021-2026) & (US$ Million) Table 19. Global Next-Generation Tumor Genetic Testing Market Share by Region (2021-2026) Table 20. Global Next-Generation Tumor Genetic Testing Market Size by Region (2027-2032) & (US$ Million) Table 21. Global Next-Generation Tumor Genetic Testing Market Share by Region (2027-2032) Table 22. Global Next-Generation Tumor Genetic Testing Revenue by Players (US$ Million) & (2021-2026) Table 23. Global Next-Generation Tumor Genetic Testing Revenue Market Share by Players (2021-2026) Table 24. Global Next-Generation Tumor Genetic Testing Key Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Next-Generation Tumor Genetic Testing Key Players Headquarters & Area Served Table 26. Global Next-Generation Tumor Genetic Testing Players, Product Type & Application Table 27. Global Next-Generation Tumor Genetic Testing Players Establishment Date Table 28. Global Players Market Concentration Ratio (CR5 and HHI) Table 29. Global Next-Generation Tumor Genetic Testing by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 30. Global Next-Generation Tumor Genetic Testing Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Next-Generation Tumor Genetic Testing Revenue by Type (2021-2026) & (US$ Million) Table 32. Global Next-Generation Tumor Genetic Testing Revenue by Type (2027-2032) & (US$ Million) Table 33. Global Next-Generation Tumor Genetic Testing Revenue Market Share by Type (2021-2026) Table 34. Global Next-Generation Tumor Genetic Testing Revenue Market Share by Type (2027-2032) Table 35. Global Next-Generation Tumor Genetic Testing Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Next-Generation Tumor Genetic Testing Revenue by Application (2021-2026) & (US$ Million) Table 37. Global Next-Generation Tumor Genetic Testing Revenue by Application (2027-2032) & (US$ Million) Table 38. Global Next-Generation Tumor Genetic Testing Revenue Market Share by Application (2021-2026) Table 39. Global Next-Generation Tumor Genetic Testing Revenue Market Share by Application (2027-2032) Table 40. Devyser Company Information Table 41. Devyser Business Overview Table 42. Devyser Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Devyser Next-Generation Tumor Genetic Testing Product Portfolio Table 44. Devyser Recent Development Table 45. Agendia Company Information Table 46. Agendia Business Overview Table 47. Agendia Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Agendia Next-Generation Tumor Genetic Testing Product Portfolio Table 49. Agendia Recent Development Table 50. Illumina Company Information Table 51. Illumina Business Overview Table 52. Illumina Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Illumina Next-Generation Tumor Genetic Testing Product Portfolio Table 54. Illumina Recent Development Table 55. Personal Genome Diagnostics Company Information Table 56. Personal Genome Diagnostics Business Overview Table 57. Personal Genome Diagnostics Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Personal Genome Diagnostics Next-Generation Tumor Genetic Testing Product Portfolio Table 59. Personal Genome Diagnostics Recent Development Table 60. Veracyte Company Information Table 61. Veracyte Business Overview Table 62. Veracyte Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Veracyte Next-Generation Tumor Genetic Testing Product Portfolio Table 64. Veracyte Recent Development Table 65. Pacific Biosciences of California Company Information Table 66. Pacific Biosciences of California Business Overview Table 67. Pacific Biosciences of California Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Pacific Biosciences of California Next-Generation Tumor Genetic Testing Product Portfolio Table 69. Pacific Biosciences of California Recent Development Table 70. Qiagen Company Information Table 71. Qiagen Business Overview Table 72. Qiagen Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Qiagen Next-Generation Tumor Genetic Testing Product Portfolio Table 74. Qiagen Recent Development Table 75. Agilent Technologies Company Information Table 76. Agilent Technologies Business Overview Table 77. Agilent Technologies Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Agilent Technologies Next-Generation Tumor Genetic Testing Product Portfolio Table 79. Agilent Technologies Recent Development Table 80. Natera Company Information Table 81. Natera Business Overview Table 82. Natera Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Natera Next-Generation Tumor Genetic Testing Product Portfolio Table 84. Natera Recent Development Table 85. Bio Rad Laboratories Company Information Table 86. Bio Rad Laboratories Business Overview Table 87. Bio Rad Laboratories Next-Generation Tumor Genetic Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Bio Rad Laboratories Next-Generation Tumor Genetic Testing Product Portfolio Table 89. Bio Rad Laboratories Recent Development Table 90. Myriad Genetics Company Information Table 91. Myriad Genetics Business Overview Table 92. Myriad Genetics Next-Generation Tumor Genetic Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Myriad Genetics Next-Generation Tumor Genetic Testing Product Portfolio Table 94. Myriad Genetics Recent Development Table 95. North America Next-Generation Tumor Genetic Testing Revenue by Type (2021-2026) & (US$ Million) Table 96. North America Next-Generation Tumor Genetic Testing Revenue by Type (2027-2032) & (US$ Million) Table 97. North America Next-Generation Tumor Genetic Testing Revenue by Application (2021-2026) & (US$ Million) Table 98. North America Next-Generation Tumor Genetic Testing Revenue by Application (2027-2032) & (US$ Million) Table 99. North America Next-Generation Tumor Genetic Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. North America Next-Generation Tumor Genetic Testing Revenue by Country (2021-2026) & (US$ Million) Table 101. North America Next-Generation Tumor Genetic Testing Revenue by Country (US$ Million) & (2027-2032) Table 102. Europe Next-Generation Tumor Genetic Testing Revenue by Type (2021-2026) & (US$ Million) Table 103. Europe Next-Generation Tumor Genetic Testing Revenue by Type (2027-2032) & (US$ Million) Table 104. Europe Next-Generation Tumor Genetic Testing Revenue by Application (2021-2026) & (US$ Million) Table 105. Europe Next-Generation Tumor Genetic Testing Revenue by Application (2027-2032) & (US$ Million) Table 106. Europe Next-Generation Tumor Genetic Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. Europe Next-Generation Tumor Genetic Testing Revenue by Country (2021-2026) & (US$ Million) Table 108. Europe Next-Generation Tumor Genetic Testing Revenue by Country (US$ Million) & (2027-2032) Table 109. China Next-Generation Tumor Genetic Testing Revenue by Type (2021-2026) & (US$ Million) Table 110. China Next-Generation Tumor Genetic Testing Revenue by Type (2027-2032) & (US$ Million) Table 111. China Next-Generation Tumor Genetic Testing Revenue by Application (2021-2026) & (US$ Million) Table 112. China Next-Generation Tumor Genetic Testing Revenue by Application (2027-2032) & (US$ Million) Table 113. Asia Next-Generation Tumor Genetic Testing Revenue by Type (2021-2026) & (US$ Million) Table 114. Asia Next-Generation Tumor Genetic Testing Revenue by Type (2027-2032) & (US$ Million) Table 115. Asia Next-Generation Tumor Genetic Testing Revenue by Application (2021-2026) & (US$ Million) Table 116. Asia Next-Generation Tumor Genetic Testing Revenue by Application (2027-2032) & (US$ Million) Table 117. Asia Next-Generation Tumor Genetic Testing Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 118. Asia Next-Generation Tumor Genetic Testing Revenue by Region (US$ Million) & (2021-2026) Table 119. Asia Next-Generation Tumor Genetic Testing Revenue by Region (US$ Million) & (2027-2032) Table 120. SAMEA Next-Generation Tumor Genetic Testing Revenue by Type (2021-2026) & (US$ Million) Table 121. SAMEA Next-Generation Tumor Genetic Testing Revenue by Type (2027-2032) & (US$ Million) Table 122. SAMEA Next-Generation Tumor Genetic Testing Revenue by Application (2021-2026) & (US$ Million) Table 123. SAMEA Next-Generation Tumor Genetic Testing Revenue by Application (2027-2032) & (US$ Million) Table 124. SAMEA Next-Generation Tumor Genetic Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. SAMEA Next-Generation Tumor Genetic Testing Revenue by Country (2021-2026) & (US$ Million) Table 126. SAMEA Next-Generation Tumor Genetic Testing Revenue by Country (US$ Million) & (2027-2032) Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Next-Generation Tumor Genetic Testing Image Figure 2. Global Next-Generation Tumor Genetic Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Next-Generation Tumor Genetic Testing Market Size Share 2021 VS 2025 VS 2032 Figure 4. Fluorescence In Situ Hybridization Image Figure 5. Polymerase Chain Reaction Image Figure 6. Microarray Technology Image Figure 7. Serum Proteomics Image Figure 8. Nucleic Acid Sequencing Image Figure 9. Global Next-Generation Tumor Genetic Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Next-Generation Tumor Genetic Testing Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospitals Image Figure 12. Speciality Clinics Image Figure 13. Research Institutes Image Figure 14. Diagnostics Laboratories Image Figure 15. Biopharmaceutical Companies Image Figure 16. Global Next-Generation Tumor Genetic Testing Market Size (US$ Million) & (2021-2032) Figure 17. Global Next-Generation Tumor Genetic Testing Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Next-Generation Tumor Genetic Testing Market Share by Region: 2021 VS 2025 VS 2032 Figure 19. Global Next-Generation Tumor Genetic Testing Players Revenue Share Top 10 and Top 5 in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Next-Generation Tumor Genetic Testing Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Next-Generation Tumor Genetic Testing Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Next-Generation Tumor Genetic Testing Revenue Market Share by Type (2021-2032) Figure 24. Global Next-Generation Tumor Genetic Testing Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Next-Generation Tumor Genetic Testing Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 26. Global Next-Generation Tumor Genetic Testing Revenue Market Share by Application (2021-2032) Figure 27. North America Next-Generation Tumor Genetic Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 28. North America Next-Generation Tumor Genetic Testing Revenue Share by Type (2021-2032) Figure 29. North America Next-Generation Tumor Genetic Testing Revenue Share by Application (2021-2032) Figure 30. North America Next-Generation Tumor Genetic Testing Revenue Share by Country (2021-2032) Figure 31. United States Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Canada Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Mexico Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Europe Next-Generation Tumor Genetic Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 35. Europe Next-Generation Tumor Genetic Testing Revenue Share by Type (2021-2032) Figure 36. Europe Next-Generation Tumor Genetic Testing Revenue Share by Application (2021-2032) Figure 37. Europe Next-Generation Tumor Genetic Testing Revenue Share by Country (2021-2032) Figure 38. Germany Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. France Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. U.K. Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Italy Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Spain Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Russia Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Netherlands Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Nordic Countries Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. China Next-Generation Tumor Genetic Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. China Next-Generation Tumor Genetic Testing Revenue Share by Type (2021-2032) Figure 48. China Next-Generation Tumor Genetic Testing Revenue Share by Application (2021-2032) Figure 49. Asia Next-Generation Tumor Genetic Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 50. Asia Next-Generation Tumor Genetic Testing Revenue Share by Type (2021-2032) Figure 51. Asia Next-Generation Tumor Genetic Testing Revenue Share by Application (2021-2032) Figure 52. Asia Next-Generation Tumor Genetic Testing Revenue Share by Region (2021-2032) Figure 53. Japan Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. South Korea Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. India Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Australia Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Taiwan Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Southeast Asia Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. SAMEA Next-Generation Tumor Genetic Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 60. SAMEA Next-Generation Tumor Genetic Testing Revenue Share by Type (2021-2032) Figure 61. SAMEA Next-Generation Tumor Genetic Testing Revenue Share by Application (2021-2032) Figure 62. SAMEA Next-Generation Tumor Genetic Testing Revenue Share by Country (2021-2032) Figure 63. Brazil Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Argentina Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Chile Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Colombia Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Peru Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Saudi Arabia Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Israel Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. UAE Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Turkey Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Iran Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Egypt Next-Generation Tumor Genetic Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Fluorescence In Situ Hybridization
  • Polymerase Chain Reaction
  • Microarray Technology
  • Serum Proteomics
  • Nucleic Acid Sequencing
Applications
  • Hospitals
  • Speciality Clinics
  • Research Institutes
  • Diagnostics Laboratories
  • Biopharmaceutical Companies
Companies covered
  • Devyser
  • Agendia
  • Illumina
  • Personal Genome Diagnostics
  • Veracyte
  • Pacific Biosciences of California
  • Qiagen
  • Agilent Technologies
  • Natera
  • Bio Rad Laboratories
  • Myriad Genetics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Next-Generation Tumor Genetic Testing Market by Type
  3. 1.2.1 Global Next-Generation Tumor Genetic Testing Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Fluorescence In Situ Hybridization
  5. 1.2.3 Polymerase Chain Reaction
  6. 1.2.4 Microarray Technology
  7. 1.2.5 Serum Proteomics
  8. 1.2.6 Nucleic Acid Sequencing
  9. 1.3 Next-Generation Tumor Genetic Testing Market by Application
  10. 1.3.1 Global Next-Generation Tumor Genetic Testing Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospitals
  12. 1.3.3 Speciality Clinics
  13. 1.3.4 Research Institutes
  14. 1.3.5 Diagnostics Laboratories
  15. 1.3.6 Biopharmaceutical Companies
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Next-Generation Tumor Genetic Testing Market Dynamics
  1. 2.1 Next-Generation Tumor Genetic Testing Industry Trends
  2. 2.2 Next-Generation Tumor Genetic Testing Industry Drivers
  3. 2.3 Next-Generation Tumor Genetic Testing Industry Opportunities and Challenges
  4. 2.4 Next-Generation Tumor Genetic Testing Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Next-Generation Tumor Genetic Testing Market Perspective (2021-2032)
  2. 3.2 Global Next-Generation Tumor Genetic Testing Growth Trends by Region
  3. 3.2.1 Global Next-Generation Tumor Genetic Testing Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Next-Generation Tumor Genetic Testing Market Size by Region (2021-2026)
  5. 3.2.3 Global Next-Generation Tumor Genetic Testing Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Next-Generation Tumor Genetic Testing Revenue by Players
  2. 4.1.1 Global Next-Generation Tumor Genetic Testing Revenue by Players (2021-2026)
  3. 4.1.2 Global Next-Generation Tumor Genetic Testing Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Next-Generation Tumor Genetic Testing Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Next-Generation Tumor Genetic Testing Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Next-Generation Tumor Genetic Testing Key Players Headquarters & Area Served
  7. 4.4 Global Next-Generation Tumor Genetic Testing Players, Product Type & Application
  8. 4.5 Global Next-Generation Tumor Genetic Testing Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Next-Generation Tumor Genetic Testing Market CR5 and HHI
  11. 4.6.3 2025 Next-Generation Tumor Genetic Testing Tier 1, Tier 2, and Tier 3
5 Next-Generation Tumor Genetic Testing Market Size by Type
  1. 5.1 Global Next-Generation Tumor Genetic Testing Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Next-Generation Tumor Genetic Testing Revenue by Type (2021-2032)
  3. 5.3 Global Next-Generation Tumor Genetic Testing Revenue Market Share by Type (2021-2032)
6 Next-Generation Tumor Genetic Testing Market Size by Application
  1. 6.1 Global Next-Generation Tumor Genetic Testing Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Next-Generation Tumor Genetic Testing Revenue by Application (2021-2032)
  3. 6.3 Global Next-Generation Tumor Genetic Testing Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Devyser
  2. 7.1.1 Devyser Company Information
  3. 7.1.2 Devyser Business Overview
  4. 7.1.3 Devyser Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Devyser Next-Generation Tumor Genetic Testing Product Portfolio
  6. 7.1.5 Devyser Recent Developments
  7. 7.2 Agendia
  8. 7.2.1 Agendia Company Information
  9. 7.2.2 Agendia Business Overview
  10. 7.2.3 Agendia Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Agendia Next-Generation Tumor Genetic Testing Product Portfolio
  12. 7.2.5 Agendia Recent Developments
  13. 7.3 Illumina
  14. 7.3.1 Illumina Company Information
  15. 7.3.2 Illumina Business Overview
  16. 7.3.3 Illumina Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Illumina Next-Generation Tumor Genetic Testing Product Portfolio
  18. 7.3.5 Illumina Recent Developments
  19. 7.4 Personal Genome Diagnostics
  20. 7.4.1 Personal Genome Diagnostics Company Information
  21. 7.4.2 Personal Genome Diagnostics Business Overview
  22. 7.4.3 Personal Genome Diagnostics Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Personal Genome Diagnostics Next-Generation Tumor Genetic Testing Product Portfolio
  24. 7.4.5 Personal Genome Diagnostics Recent Developments
  25. 7.5 Veracyte
  26. 7.5.1 Veracyte Company Information
  27. 7.5.2 Veracyte Business Overview
  28. 7.5.3 Veracyte Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Veracyte Next-Generation Tumor Genetic Testing Product Portfolio
  30. 7.5.5 Veracyte Recent Developments
  31. 7.6 Pacific Biosciences of California
  32. 7.6.1 Pacific Biosciences of California Company Information
  33. 7.6.2 Pacific Biosciences of California Business Overview
  34. 7.6.3 Pacific Biosciences of California Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Pacific Biosciences of California Next-Generation Tumor Genetic Testing Product Portfolio
  36. 7.6.5 Pacific Biosciences of California Recent Developments
  37. 7.7 Qiagen
  38. 7.7.1 Qiagen Company Information
  39. 7.7.2 Qiagen Business Overview
  40. 7.7.3 Qiagen Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Qiagen Next-Generation Tumor Genetic Testing Product Portfolio
  42. 7.7.5 Qiagen Recent Developments
  43. 7.8 Agilent Technologies
  44. 7.8.1 Agilent Technologies Company Information
  45. 7.8.2 Agilent Technologies Business Overview
  46. 7.8.3 Agilent Technologies Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Agilent Technologies Next-Generation Tumor Genetic Testing Product Portfolio
  48. 7.8.5 Agilent Technologies Recent Developments
  49. 7.9 Natera
  50. 7.9.1 Natera Company Information
  51. 7.9.2 Natera Business Overview
  52. 7.9.3 Natera Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Natera Next-Generation Tumor Genetic Testing Product Portfolio
  54. 7.9.5 Natera Recent Developments
  55. 7.10 Bio Rad Laboratories
  56. 7.10.1 Bio Rad Laboratories Company Information
  57. 7.10.2 Bio Rad Laboratories Business Overview
  58. 7.10.3 Bio Rad Laboratories Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Bio Rad Laboratories Next-Generation Tumor Genetic Testing Product Portfolio
  60. 7.10.5 Bio Rad Laboratories Recent Developments
  61. 7.11 Myriad Genetics
  62. 7.11.1 Myriad Genetics Company Information
  63. 7.11.2 Myriad Genetics Business Overview
  64. 7.11.3 Myriad Genetics Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Myriad Genetics Next-Generation Tumor Genetic Testing Product Portfolio
  66. 7.11.5 Myriad Genetics Recent Developments
8 North America
  1. 8.1 North America Next-Generation Tumor Genetic Testing Revenue (2021-2032)
  2. 8.2 North America Next-Generation Tumor Genetic Testing Revenue by Type (2021-2032)
  3. 8.2.1 North America Next-Generation Tumor Genetic Testing Revenue by Type (2021-2026)
  4. 8.2.2 North America Next-Generation Tumor Genetic Testing Revenue by Type (2027-2032)
  5. 8.3 North America Next-Generation Tumor Genetic Testing Revenue Share by Type (2021-2032)
  6. 8.4 North America Next-Generation Tumor Genetic Testing Revenue by Application (2021-2032)
  7. 8.4.1 North America Next-Generation Tumor Genetic Testing Revenue by Application (2021-2026)
  8. 8.4.2 North America Next-Generation Tumor Genetic Testing Revenue by Application (2027-2032)
  9. 8.5 North America Next-Generation Tumor Genetic Testing Revenue Share by Application (2021-2032)
  10. 8.6 North America Next-Generation Tumor Genetic Testing Revenue by Country
  11. 8.6.1 North America Next-Generation Tumor Genetic Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Next-Generation Tumor Genetic Testing Revenue by Country (2021-2026)
  13. 8.6.3 North America Next-Generation Tumor Genetic Testing Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Next-Generation Tumor Genetic Testing Revenue (2021-2032)
  2. 9.2 Europe Next-Generation Tumor Genetic Testing Revenue by Type (2021-2032)
  3. 9.2.1 Europe Next-Generation Tumor Genetic Testing Revenue by Type (2021-2026)
  4. 9.2.2 Europe Next-Generation Tumor Genetic Testing Revenue by Type (2027-2032)
  5. 9.3 Europe Next-Generation Tumor Genetic Testing Revenue Share by Type (2021-2032)
  6. 9.4 Europe Next-Generation Tumor Genetic Testing Revenue by Application (2021-2032)
  7. 9.4.1 Europe Next-Generation Tumor Genetic Testing Revenue by Application (2021-2026)
  8. 9.4.2 Europe Next-Generation Tumor Genetic Testing Revenue by Application (2027-2032)
  9. 9.5 Europe Next-Generation Tumor Genetic Testing Revenue Share by Application (2021-2032)
  10. 9.6 Europe Next-Generation Tumor Genetic Testing Revenue by Country
  11. 9.6.1 Europe Next-Generation Tumor Genetic Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Next-Generation Tumor Genetic Testing Revenue by Country (2021-2026)
  13. 9.6.3 Europe Next-Generation Tumor Genetic Testing Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Next-Generation Tumor Genetic Testing Revenue (2021-2032)
  2. 10.2 China Next-Generation Tumor Genetic Testing Revenue by Type (2021-2032)
  3. 10.2.1 China Next-Generation Tumor Genetic Testing Revenue by Type (2021-2026)
  4. 10.2.2 China Next-Generation Tumor Genetic Testing Revenue by Type (2027-2032)
  5. 10.3 China Next-Generation Tumor Genetic Testing Revenue Share by Type (2021-2032)
  6. 10.4 China Next-Generation Tumor Genetic Testing Revenue by Application (2021-2032)
  7. 10.4.1 China Next-Generation Tumor Genetic Testing Revenue by Application (2021-2026)
  8. 10.4.2 China Next-Generation Tumor Genetic Testing Revenue by Application (2027-2032)
  9. 10.5 China Next-Generation Tumor Genetic Testing Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Next-Generation Tumor Genetic Testing Revenue (2021-2032)
  2. 11.2 Asia Next-Generation Tumor Genetic Testing Revenue by Type (2021-2032)
  3. 11.2.1 Asia Next-Generation Tumor Genetic Testing Revenue by Type (2021-2026)
  4. 11.2.2 Asia Next-Generation Tumor Genetic Testing Revenue by Type (2027-2032)
  5. 11.3 Asia Next-Generation Tumor Genetic Testing Revenue Share by Type (2021-2032)
  6. 11.4 Asia Next-Generation Tumor Genetic Testing Revenue by Application (2021-2032)
  7. 11.4.1 Asia Next-Generation Tumor Genetic Testing Revenue by Application (2021-2026)
  8. 11.4.2 Asia Next-Generation Tumor Genetic Testing Revenue by Application (2027-2032)
  9. 11.5 Asia Next-Generation Tumor Genetic Testing Revenue Share by Application (2021-2032)
  10. 11.6 Asia Next-Generation Tumor Genetic Testing Revenue by Country
  11. 11.6.1 Asia Next-Generation Tumor Genetic Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Next-Generation Tumor Genetic Testing Revenue by Country (2021-2026)
  13. 11.6.3 Asia Next-Generation Tumor Genetic Testing Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Next-Generation Tumor Genetic Testing Revenue (2021-2032)
  2. 12.2 SAMEA Next-Generation Tumor Genetic Testing Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Next-Generation Tumor Genetic Testing Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Next-Generation Tumor Genetic Testing Revenue by Type (2027-2032)
  5. 12.3 SAMEA Next-Generation Tumor Genetic Testing Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Next-Generation Tumor Genetic Testing Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Next-Generation Tumor Genetic Testing Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Next-Generation Tumor Genetic Testing Revenue by Application (2027-2032)
  9. 12.5 SAMEA Next-Generation Tumor Genetic Testing Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Next-Generation Tumor Genetic Testing Revenue by Country
  11. 12.6.1 SAMEA Next-Generation Tumor Genetic Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Next-Generation Tumor Genetic Testing Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Next-Generation Tumor Genetic Testing Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst